<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916629</url>
  </required_header>
  <id_info>
    <org_study_id>AB-DRUG-PHOTOCIL-PS-001</org_study_id>
    <nct_id>NCT01916629</nct_id>
  </id_info>
  <brief_title>Photocil (Topical) for the Treatment of Psoriasis Vulgaris</brief_title>
  <official_title>Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Biology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Biology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Photocil is a topical drug (cream) that selectively delivers Narrow Band - Ultraviolet B
      (NB-UVB) therapy when exposed to sunlight. Photocil is intended to help protect users from
      non-therapeutic Ultraviolet B (UVB) radiation while selectively passing wavelengths of light
      in the NB-UVB range with peak transmission of 308nm. The aim of the study is to assess the
      safety and efficacy of Photocil in the treatment of psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NB-UVB phototherapy is a common treatment for patients with psoriasis, and has been reported
      to be safe and effective in numerous clinical trials. Clinical trials have reported
      achievement of Psoriasis Area Severity Index (PASI)-75 in 50-70% of patients after 4-6 weeks
      of NB-UVB treatment.

      Many drawbacks limit patients compliance, access, and acceptance of traditional NB-UVB
      phototherapy. The strict treatment regimen (2-3 sessions per week for an average of 12 weeks
      or more) performed at a specialized phototherapy clinic combined with high cost and low or no
      reimbursement make compliance and access a major drawback.

      In order to address the drawbacks of phototherapy, we developed a novel topical cream -
      Photocil - that selectively delivers NB-UVB therapy when exposed to sunlight. When used with
      natural sunlight, Photocil provides a convenient alternative to traditional clinic based
      phototherapy; thus, has the potential to dramatically increase patient compliance and
      treatment outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Lesion Clearance</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Photocil for Psoriasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Drug - Photocil for Psoriasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Sunscreen (SPF 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - Sunscreen (SPF 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photocil for Psoriasis</intervention_name>
    <description>Photocil for Psoriasis</description>
    <arm_group_label>Photocil for Psoriasis</arm_group_label>
    <other_name>Photocil for Psoriasis (U.S. FDA NDC: 54841-001-01)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo - Sunscreen (SPF 2)</intervention_name>
    <description>Placebo - Sunscreen (SPF 2)</description>
    <arm_group_label>Placebo - Sunscreen (SPF 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with psoriasis vulgaris confirmed by a dermatologist

          -  Psoriasis lesions affecting at a minimum 5% of the facial, legs, or arms surface area

          -  ï¿¼Age: 18 to 65

          -  Participants able to give informed consent

        Exclusion Criteria:

          -  Subject did not respond to prior phototherapy treatment

          -  Subject completed phototherapy for same lesion(s) in last 6 months

          -  Subject has previous history of skin cancer

          -  Subject has previous history of photosensitivity

          -  Subject has a history of herpes (HSV I or II) outbreaks

          -  Subject has previous history of autoimmune disease may be excluded at investigator's
             discretion

          -  Subject is currently taking of immunosuppressive or photosensitizing drugs

          -  Subject plans to use antibiotics, anti-fungal, calcineurin inhibitors or other drugs
             that may cause photosensitivity during the study period. These patients may be
             excluded at investigator's discretion

          -  Subject is pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McCoy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Applied Biology, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Physicians Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <results_first_submitted>December 11, 2015</results_first_submitted>
  <results_first_submitted_qc>February 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2016</results_first_posted>
  <last_update_submitted>February 12, 2016</last_update_submitted>
  <last_update_submitted_qc>February 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunscreening Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Photocil for Psoriasis</title>
          <description>Active Drug - Photocil for Psoriasis
Photocil for Psoriasis: Photocil for Psoriasis</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Sunscreen (SPF 2)</title>
          <description>Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Photocil for Psoriasis</title>
          <description>Active Drug - Photocil for Psoriasis
Photocil for Psoriasis: Photocil for Psoriasis</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Sunscreen (SPF 2)</title>
          <description>Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="9.7"/>
                    <measurement group_id="B2" value="35" spread="14"/>
                    <measurement group_id="B3" value="41" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Lesion Clearance</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Photocil for Psoriasis</title>
            <description>Active Drug - Photocil for Psoriasis
Photocil for Psoriasis: Photocil for Psoriasis</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Sunscreen (SPF 2)</title>
            <description>Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Lesion Clearance</title>
          <units>Percent Clearance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" spread="23.7"/>
                    <measurement group_id="O2" value="8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Photocil for Psoriasis</title>
          <description>Active Drug - Photocil for Psoriasis
Photocil for Psoriasis: Photocil for Psoriasis</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Sunscreen (SPF 2)</title>
          <description>Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Keene, MD</name_or_title>
      <organization>Physicians Institute</organization>
      <phone>(520) 290-5555</phone>
      <email>monican@appliedbiology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

